top of page
Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
- Sep 11, 2022
Acceptance in Major Peer-Reviewed Journals of two Landmark Pre-Clinical Studies
Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Alpha DaRT Treatment and Standard-of-Care Immunotherapy, Chemotherapy and Anti-Angiogenic Therapy - Study on combination with anti-PD1 therapy published by International Journal of Radiation Oncology, Biology, Physics, known in
- Sep 6, 2022
Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer
JERUSALEM, September 1, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Company’s Board of Directors in order to assume the full-time position of Alpha Tau’s Chief Commercial Officer. Mr. Melnyk served most recently as CEO of Fortovia Therapeutics, an oncology supportive care pharmaceutical and me
bottom of page